4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CD11b immunophenotyping identifies inflammatory profiles in the mouse and human lungs

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The development of easily accessible tools for human immunophenotyping to classify patients into discrete disease endotypes is advancing personalized therapy. However, no systematic approach has been developed for the study of inflammatory lung diseases with often complex and highly heterogeneous disease etiologies. We have devised an internally standardized flow cytometry approach that can identify parallel inflammatory alveolar macrophage phenotypes in both the mouse and human lungs. In mice, lung innate immune cell alterations during endotoxin challenge, influenza virus infection, and in two genetic models of chronic obstructive lung disease could be segregated based on the presence or absence of CD11b alveolar macrophage upregulation and lung eosinophilia. Additionally, heightened alveolar macrophage CD11b expression was a novel feature of acute lung exacerbations in the SHIP-1 −/− model of chronic obstructive lung disease, and anti-CD11b antibody administration selectively blocked inflammatory CD11b pos but not homeostatic CD11b neg alveolar macrophages in vivo. The identification of analogous profiles in respiratory disease patients highlights this approach as a translational avenue for lung disease endotyping and suggests that heterogeneous innate immune cell phenotypes are an underappreciated component of the human lung disease microenvironment.

          Supplementary information

          The online version of this article (doi:10.1038/mi.2015.84) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

            Establishing a CD8(+) T cell-mediated immune correlate of protection in HIV disease is crucial to the development of vaccines designed to generate cell-mediated immunity. Historically, neither the quantity nor breadth of the HIV-specific CD8(+) T-cell response has correlated conclusively with protection. Here, we assess the quality of the HIV-specific CD8(+) T-cell response by measuring 5 CD8(+) T-cell functions (degranulation, IFN-gamma, MIP-1beta, TNF-alpha, and IL-2) simultaneously in chronically HIV-infected individuals and elite nonprogressors. We find that the functional profile of HIV-specific CD8(+) T cells in progressors is limited compared to that of nonprogressors, who consistently maintain highly functional CD8(+) T cells. This limited functionality is independent of HLA type and T-cell memory phenotype, is HIV-specific rather than generalized, and is not effectively restored by therapeutic intervention. Whereas the total HIV-specific CD8(+) T-cell frequency did not correlate with viral load, the frequency and proportion of the HIV-specific T-cell response with highest functionality inversely correlated with viral load in the progressors. Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alveolar macrophages: plasticity in a tissue-specific context.

              Alveolar macrophages exist in a unique microenvironment and, despite historical evidence showing that they are in close contact with the respiratory epithelium, have until recently been investigated in isolation. The microenvironment of the airway lumen has a considerable influence on many aspects of alveolar macrophage phenotype, function and turnover. As the lungs adapt to environmental challenges, so too do alveolar macrophages adapt to accommodate the ever-changing needs of the tissue. In this Review, we discuss the unique characteristics of alveolar macrophages, the mechanisms that drive their adaptation and the direct and indirect influences of epithelial cells on them. We also highlight how airway luminal macrophages function as sentinels of a healthy state and how they do not respond in a pro-inflammatory manner to antigens that do not disrupt lung structure. The unique tissue location and function of alveolar macrophages distinguish them from other macrophage populations and suggest that it is important to classify macrophages according to the site that they occupy.
                Bookmark

                Author and article information

                Contributors
                Margaret.Hibbs@monash.edu
                Journal
                Mucosal Immunol
                Mucosal Immunol
                Mucosal Immunology
                Nature Publishing Group US (New York )
                1933-0219
                1935-3456
                30 September 2015
                2016
                : 9
                : 2
                : 550-563
                Affiliations
                [1 ]GRID grid.1002.3, ISNI 0000 0004 1936 7857, Department of Immunology, , Monash University, Alfred Medical Research and Education Precinct, ; Melbourne, Australia
                [2 ]GRID grid.1008.9, ISNI 0000 0001 2179 088X, Department of Surgery, , University of Melbourne, ; Melbourne, Australia
                [3 ]GRID grid.482095.2, Ludwig Institute for Cancer Research, ; Melbourne, Australia
                [4 ]GRID grid.1018.8, ISNI 0000 0001 2342 0938, Department of Biochemistry and Genetics, , La Trobe Institute for Molecular Science, La Trobe University, ; Bundoora, Australia
                [5 ]GRID grid.416153.4, ISNI 0000 0004 0624 1200, Department of Respiratory Medicine, , Royal Melbourne Hospital, ; Parkville, Australia
                [6 ]GRID grid.1623.6, ISNI 0000 0004 0432 511X, Department of Allergy, , Immunology and Respiratory Medicine, Alfred Hospital, ; Parkville, Australia
                [7 ]GRID grid.1042.7, The Walter and Eliza Hall Institute for Medical Research, ; Parkville, Australia
                [8 ]GRID grid.1008.9, ISNI 0000 0001 2179 088X, Department of Medical Biology, , University of Melbourne, ; Melbourne, Australia
                [9 ]GRID grid.1008.9, ISNI 0000 0001 2179 088X, Department of Pharmacology, , University of Melbourne, ; Melbourne, Australia
                [10 ]GRID grid.410678.c, Present Address: 10Present address: Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria 3084, Australia., ; ,
                Article
                BFmi201584
                10.1038/mi.2015.84
                7101582
                26422753
                7c1536bf-b336-4722-9db2-4b457dfba02b
                © Society for Mucosal Immunology 2016

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 19 February 2015
                : 12 July 2015
                Categories
                Article
                Custom metadata
                © Society for Mucosal Immunology 2016

                Immunology
                flow cytometry,alveolar macrophages,inflammation,respiratory tract diseases
                Immunology
                flow cytometry, alveolar macrophages, inflammation, respiratory tract diseases

                Comments

                Comment on this article